The Top 5 Biosimilar Articles for the Week of October 31

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of October 31, 2022.

Number 5: Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explored whether biosimilars should be considered a commodity and if the commodification of medications is sustainable as the market continues to expand.

Number 4: A report from Cardinal Health tells that rheumatologists are more familiar and confident in biosimilars compared with 2020, showing that education efforts are effective and that rheumatologists are more willing to prescribe biosimilars to their patients.

Number 3: Authors of a systematic review summarized the results of 21 published studies on the efficacy, safety, and cost-benefit ratio of trastuzumab biosimilars in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Number 2: Similis Bio signed a licensing and codevelopment agreement with Blau Farmacêutica, allowing the latter to have exclusive development and marketing rights to 4 biosimilar assets in Latin America.

Number 1: Genentech and Roche have voluntarily recalled their ophthalmology biobetter, Susvimo, an ocular implant for ranibizumab injection, in the United States for a possible leakage issue.

To read all of these articles and more, visit centerforbiosimilars.com.